		J	CO9 Rec'd PCT/PTO 26 FEB
FORM PTO-1 (REV. 11-200	090 U.S. DEPARTMENT OF COM	MERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER
		TO THE UNITED STATES	VGEN.P-055
_	DESIGNATED/ELECT	ED OFFICE (DO/EO/US)	U.S. APPLICATION NO. (If known, see 37 CFR 1.5
	CONCERNING A FILIN	IG UNDER 35 U.S.C. 371	n9/786105
	NATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
	2A99/01177	December 10, 1999	December 11, 1998
Metho	OFINVENTION d and Kit for the Chai	acterization of Antibiotic-	Resistance Mutations
	ANT(S) FOR DO/EO/US		
Applicar	obert Shipman at herewith submits to the United Sta	ntes Designated/Elected Office (DO/EO/US)	the following items and other information
1.17	This is a FIRST submission of items	concerning a filing under 35 U.S.C. 371.	
		NT submission of items concerning a filing t	inder 35 U.S.C. 371.
3. 🗆 1	This is an express request to begin n	ational examination procedures (35 U.S.C. 3	71(f)). The submission must include
	items (5), (6), (9) and (21) indicated	below. ration of 19 months from the priority date (A	
	A copy of the International Applicat		
		only if not communicated by the Internatio	nal Bureau).
1	b. X has been communicated by	the International Bureau.	
	c. is not required, as the appl	ication was filed in the United States Receiv	ing Office (RO/US).
6. 🔲 🛭	An English language translation of t	ne International Application as filed (35 U.S	.C. 371(c)(2)).
	a. is attached hereto.		
		itted under 35 U.S.C. 154(d)(4).	(25 H C C 27 K-V2))
_		ernational Aplication under PCT Article 19	
		ed only if not communicated by the Internati	ona: Buleau).
	_	by the International Bureau.	outs has NOT ownized
	=	ver, the time limit for making such amendm	ents has NOT expired.
1	d. have not been made and w		
8. 🔲 .	An English language translation of t	he amendments to the claims under PCT Art	icle 19 (35 U.S.C. 371 (c)(3)).
	An oath or declaration of the inventor	***	
	An English lanugage translation of t Article 36 (35 U.S.C. 371(c)(5)).	he annexes of the International Preliminary I	Examination Report under PCT
Item	s 11 to 20 below concern documen	t(s) or information included:	
11.	An Information Disclosure Statem	ent under 37 CFR 1.97 and 1.98.	
12. 👿	An assignment document for recor	rding. A separate cover sheet in compliance	with 37 CFR 3.28 and 3.31 is included.
13. 👿	A FIRST preliminary amendment		
14. 🔲	A SECOND or SUBSEQUENT p	reliminary amendment.	
15.	A substitute specification.		
16.	A change of power of attorney and	I/or address letter.	
17.	A computer-readable form of the	equence listing in accordance with PCT Rul	e 13ter.2 and 35 U.S.C. 1.821 - 1.825.
18.	A second copy of the published in	ternational application under 35 U.S.C. 154(d)(4).
19. 🔲	A second copy of the English lang	uage translation of the international applicat	ion under 35 U.S.C. 154(d)(4).
a []	Orbert Married and Indiana.		

International Preliminary Examination Report

US 09/10/70 86 1705 DITERNATIONAL APPLICATION NO. PCT/CA99/01177						ATTORNEYS DOCK	
BASIC NATIONAL	21. The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):					CULATIONS F	TO USE ONLY
Neither internations nor international se and International Se	al preliminary exa arch fee (37 CFR earch Report not)	aminatio 1.445(a prepareo	on fee (37 CFR 1.482) (2)) paid to USPTO 1 by the EPO or JPO	\$1000.00			
International prelim USPTO but Interna	inary examinatio tional Search Re	n fee (3 port pre	7 CFR 1.482) not paid to pared by the EPO or JPO	\$860.00			
International prelim but international ser	ninary examinatio arch fee (37 CFR	n fee (3 1.445(a	7 CFR 1.482) not paid to ((2)) paid to USPTO	USPTO \$710.00			
but all claims did n	ot satisfy provisio	ns of P	7 CFR 1.482) paid to US CT Article 33(1)-(4)	2690.00			
and all claims satist	fied provisions of	PCT A	7 CFR 1.482) paid to US rticle 33(1)-(4)	\$100.00	<u> </u>	000 00	
ENTE	R APPROPRI	ATE	BASIC FEE AMOU	UNT =	\$	860.00	
Surcharge of \$130.00 months from the earl	0 for furnishing the iest claimed prior	ne oath ority date	or declaration later than (37 CFR 1.492(e)).	20 30	\$		
CLAIMS	NUMBER FIL		NUMBER EXTRA	RATE	\$		
Total claims	21 - 20		1	x \$18.00	\$	18.00	
Independent claims MULTIPLE DEPEN	2 -3		diaghla)	x \$80.00 + \$270.00	\$		
WOLTIFES DEFEN			F ABOVE CALCU			878.00	
Applicant claim are reduced by	s small entity stat		37 CFR 1.27. The fees i		\$	439.00	
			SU	JBTOTAL =	\$	439.00	
Processing fee of \$1 months from the ear	30.00 for furnishi liest claimed prio	ng the I rity date	-		\$		
TOTAL NATIONAL FEE =			\$				
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +			\$				
TOTAL FEES ENCLOSED =			\$	439.00			
					Amo	ount to be refunded:	s
					<u> </u>	charged:	3
b. Please char	the amount of \$ ge my Deposit A copy of this she	ccount 1		e above fees is enclo the amount of \$	sed.	to cover the	above fees.
c. X The Commo	issioner is hereby	authori	ized to charge any addition 15-0610 A duplic	mal fees which may ate copy of this shee	oe requ t is end	nired, or credit and losed.	шу
			rd. WARNING: Information on this form. Provide				
			under 37 CFR 1.494 or to restore the application			petition to reviv	re (37 CFR
SEND ALL CORRESPONDED AHL		LLP	•	SIGNATI	JRE	u Sh	us)
				Mari	.na	T. Larso	n, Ph.D.
021	121			32,0	38		
PATENT TRACEM				REGISTI	RATION	NUMBER	
PRITENT INNOENT	write.						

JC03 Rec'd PCT/PT0 2 6 FFB 2001

VGEN.P-055

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant Shipman Serial No. TBA

Filed Herewith

Method and Kit for Characterization of Antibiotic-Resistance Title

Mutations in Mycobacterium Tuberculosis

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents U.S. Patent and Trademark Office Washington, D.C. 20231

Sir:

Preliminary to the examination of the US national phase of PCT/CA99/01177 which is filed herewith, please make the following amendments to the claims, as amended before the IPEA/EP:

In the claims:

In claim 3, line 1, delete "claim 3" and insert - - claim 2 - -. In claim 4, line 1, delete "any of claims 1 to 3" and insert - - claim 1 - -. In claim 5, line 1, delete "any of claims 1 to 4" and insert - - claim 1 - -. In claim 6, line 1, delete "any of claims 1 to 5" and insert - - claim 1 - -. In claim 7, line 1, delete "any of claims 1 to 6" and insert - - claim 1 - -. In claim 8, line 1, delete "any of claims 1 to 7" and insert - - claim 1 - -. In claim 9, line 1, delete "any of claims 1 to 8" and insert - - claim 1 - -.

I hereby certify that this paper and the attachments named herein are being deposited with the United States Postal Service as Express Mail # EL 55613145645 in an envelope addressed to the Assistant Commissioner of Patents and Trademarks, Washington, D.C. 20231 on 2/26/2001

2/26/2001 Date

In claim 10, line 1, delete "any of claims 1 to 9" and insert - - claim 1 - -.

In claim 11, line 1, delete "any of claims 1 to 10" and insert - - claim 1 - -.

In claim 12, line 1, delete "any of claims 2 to 11" and insert - - claim 2 - -.

In claim 13, line 1, delete "any of claims 2 to 12" and insert - - claim 2 - -.

Please add the following claims:

- 15. The method of claim 4 wherein the first sequencing procedure for katG is performed using amplification primers as set forth in Seq. ID Nos. 6 and 7 and sequencing primers as set forth in Seq. ID. Nos. 8 and 9.
- 16. The method of claim 15 wherein the first sequencing procedure for 23S is performed using amplification primers as set forth in Seq. ID. Nos. 46 and 47 and sequencing primers as set forth in Seq. ID. Nos. 48 and 49.
- 17. The method of claim 16 wherein the second sequencing procedure for PR is performed using amplification primers as set forth in Seq. ID Nos. 11 and 12 and sequencing primers as set forth in Seq. ID. Nos. 13 and 14.
- 18. The method of claim 17 wherein the second sequencing procedure for pncA is performed using amplification primers as set forth in Seq. ID Nos. 36 and 37 and sequencing primers as set forth in Seq. ID. Nos. 38 and 39.
- 19. The method of claim 18 wherein the second sequencing procedure for embB is performed using amplification primers as set forth in Seq. ID Nos. 31 and 32 and sequencing primers as set forth in Seq. ID. Nos. 33 and 34.
- The method of claim 19 wherein the second sequencing procedure for gyrA
 is performed using amplification primers as set forth in Seq. ID Nos. 41 and 42 and
 sequencing primers as set forth in Seq. ID. Nos. 43 and 44.
- The method of claim 20, wherein the third sequencing procedure for 16S/rrs is performed using amplification primers as set forth in Seq. ID Nos. 26 and 27 and sequencing primers as set forth in Seq. ID Nos. 28 and 29.

This amendment has been prepared to eliminate multiple dependencies. No new matter has been

added.

Respectfully submitted,

OPPEDAHL & LARSON LLP

Marina T. Larson, Ph.D. Reg. No. 32,038 P.O. Box 5068

Dillon, Co. 80435-5068

09/786105 Rec'd PCT/PTO 26 FEB 2001

- 1 -

METHOD AND KIT FOR THE CHARACTERIZATION OF ANTIBIOTIC-RESISTANCE MUTATIONS IN MYCOBACTERIUM TUBERCULOSIS

DESCRIPTION

Field of the Invention

This application relates to a method and kit for the characterization of antibiotic resistance mutations in *Mycobacterium tuberculosis*, and particularly to the evaluation of such mutations in clinical samples.

Background of the Invention

M. tuberculosis can be resistant to all antibiotics that are currently used to treat tuberculosis patients. Antibiotic resistance is due to acquired point mutations in target genes in the genome of M. tuberculosis. These point mutations render the organism insensitive to the action of the antibiotic by preventing it's uptake or activation, or by altering the antibiotic target. The observed antibiotic resistance in M. tuberculosis is not due to an episome-encoded resistance gene transferred from one strain to another and, like other bacteria, is single-step (one point mutation), high-level resistance.

Rapid and accurate detection of antibiotic resistance in *Mycobacterium* tuberculosis in sputum samples would greatly improve both patient treatment and outcome. Presently, analysis of *M. tuberculosis* is carried out on DNA recovered from sputum samples handled according to Standard Infectious Disease/Public Health Laboratory practices. The sputum sample is decontaminated and a cell sediment isolated. This cell sediment is the sample source for all routine procedures used in the detection and isolation of *M. tuberculosis*. Portions of this sample are used in BacTec cultures for selective growth of *M. tuberculosis*, agar plate/agar slant cultures for *M. tuberculosis*, acid-fast bacilli (AFB) smears for mycobacteria detection and molecular biological methods for the detection of M. tuberculosis and atypical mycobacteria. (See Fig. 1)

Mycobacterial DNA is prepared directly from the decontaminated sputum cell sediments according to standard procedures and this mycobacterial DNA is used in the various molecular biological detection procedures. The methods presently in use for the detection of M. tuberculosis are either PCR-based or probe-based. These tests are used

Rifampin

primarily on AFB smear-positive samples. Since the presence of M. tuberculosis has already been established by the AFB smear, these tests are used primarily in a confirmatory capacity as opposed to a diagnostic capacity. Furthermore, these tests provide no information on the potential antibiotic resistance of these M. tuberculosis samples.

Below is a list of antibiotics used to treat *M. Tuherculoris* infections. The gene target of the specific antibiotic and regions associated with antibiotic resistance are listed, if known. The references on which the codon assignments are based are listed at the end of the application.

rpoB gene

codon 507-533^a

2.	Isoniazid	katG gene	codon 275/315/328 ^b
3.	Teoniazid	mahA gene	unknown a
4.	Isoniazid	oxyR-ahpC intergenic region	(PR)
			nucleotides -48 to +33
5.	Azithomycin	236 rRNA sequence	nucleatide 2568A °
6.	Pyrazinamide	pncA gene	codon 47/85 F
7.	Ethambutol	embB gene	codon 306 s
8.	Streptomycin	rpsL/s12 gene	codon 43/88 h
9.	Streptomycin	16S/rrs sequence	nucleotides 491, 512, 516, 513,
			903, 904
10.	Ciprofloxacin	gytA gene	codon 88-95 ³

Probe-based tests do exist for the determination of nfampin resistance in M. tuberculosis (line probe assay-InnoTek), but these probes rely on prior knowledge of ambionic resistance-associated mutations in the rpoB gene. Mutations outside the region covered by the probe or new mutations not included in the probe cocktail could still confer resistance, but would not be detected using this product in it's present form.

Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy", vol. 34, page 163 (1994) describes the application of automated DNA sequence analysis of hsp65 to speciation of isolates previously-identified as being M. substracted.

WO 00/36142 PCT/CA99/01177

- 3 -

Thus, there remains a need for a method for detecting antibiotic-resistance mutations in clinical M. tuberculosis sputum samples which is capable of detecting mutations in all of the gene targets which confer antibiotic resistance. It is an object of the present invention to provide such a method. It is a further object of this invention to provide amplification and cycle sequencing primer sets, and kits containing such primer sets, for use in the characterization of antibiotic resistance mutations in M. tuberculosis.

Summary of Invention

Amplification and cycle sequencing primer sets have been developed for the detection and analysis of antibiotic resistance-associated mutations in defined regions of the rpoB (rifampin), katG (isoniazid), oxyR-ahpC PR (isoniazid), mabA (isoniazid), rpsL/s12 (streptomycin), 16S/rrs (streptomycin), embB (ethambutol), pncA (pyrazinamide), gyrA (ciprofloxacin) and 23S (azithromycin) genes. Using these primer sets and the OPENGENE™ automated DNA sequencing system, a protocol has been developed which permits both the rapid detection of M. tuberculosis and the identification of antibiotic resistance-associated mutations in a series of gene targets. The present invention uses a series of tests designed to detect antibiotic resistance-associated mutation in all gene targets for all antibiotics presently in use for the treatment of tuberculosis. The tests are employed in a hierarchical manner on both AFB smear-positive or smear-negative samples to determine both the presence and antibiotic-resistance of M. tuberculosis in a given sample. This method permits the simultaneous determination of M. tuberculosis presence in a sample and the antibiotic-resistance profile to an entire panel of antibiotics. Standard methods require from 2-6 weeks to culture M. tuberculosis and additional time to establish antibiotic resistance. Although DNA sequence-based (genotypic) tests are not intended to replace the traditional culture-based (phenotypic) methods, these tests do represent a rapid, sensitive and accurate protocol which provides clinicians with valuable information regarding antibiotic treatment options within days as opposed to weeks.

Brief Description to the Figures

Fig. 1 shows known testing protocols for M. tuberculosis; and

WO 00/36142 PCT/CA99/01177

- 4 -

Fig. 2 shows a hierarchical assay scheme for evaluating M. tuberculosis type in accordance with the invention.

Detailed Description of the Invention

In accordance with the invention, regions of the genome of *M. tuberculosis* associated with antibiotic resistance are amplified and sequenced using specifically designed amplification and sequencing primers. Various techniques for amplification are known, including the basic PCR amplification techniques described in US Patent No. 4,683,202, which is incorporated herein by reference. Similarly, various techniques for sequencing are know, some of which require prior amplification and some of which do not. Included among known sequencing techniques are those disclosed in US Patents Nos. 5,834,189 and 5,789,168, which are incorporated herein by reference. The primers of the invention can be used in any of these sequencing formats, although the invention is exemplified below using separate amplification and cycle-sequencing steps.

In theory, the selection of primers to amplify and sequence a known region of interest should be straightforward. In fact, however, because of the possibility of primer binding to other sites, complications arising from secondary structure, and other factors which are not fully understood, some primers perform better than others for amplification and sequencing of the same region of interest. The present invention provides primers which have been optimized for the amplification and sequencing of regions associated with each of the ten known types of antibiotic resistance. These primer sets are shown below, along with the sequence of the genes that they are used to analyze. In the gene sequences, the locations of the primers are underlined.

Primers

rpoB (rifampin resistance)

rpoB-F amplification primer, 20-mer, bp2201-2220 5' TAC GGT CGG CGA GCT GAT CC 3' rpoB-R amplification primer, 20-mer, bp2611-2592

5' TAC GGC GTT TCG ATG AAC CC 3'

SEQ. ID NO. 1

SEQ ID NO. 2

rpoB-5s sequencing primer, 20-mer, bp2201-2220

5' TAC GGT CGG CGA GCT GAT CC 3'

rpoB-3s sequencing primer, 20-mer, bp2611-2592

5' TAC GGC GTT TCG ATG AAC CC 3'

SEQ ID NO. 3

SEQ ID NO. 4

SEQ. ID. NO. 5

2161 aaaccgacga categaccac tteggcaacc geegeetgeg tagggegge gagctgatec 2221 aaaaccagat eegggtegge atgtegegga tggagegggt ggteeggga eggatgacca 2281 ceeaggacgt ggaggegate acacegeaga egttgateaa categgeeg gtggtegeg 2341 egateaagga gttettegge accagecage tgagecaatt eatggaceag acaaaccege 2401 tgteggggtt gaccacaaag egegactgt eggagetgag geegggggt etgteaetgg 2461 agetgeegg getggaggte eggaacgte accegtega etaeggegg atgtgeega 2521 tegaaaccee tgaggggee aacateggte tgateggte getggtegtg taeggeggg 2581 teaaccegtt egggtteate gaaagcegt accgaatggt ggtegaegge gtggttaacg

katG (isoniazid resistance)

katG-F amplification primer, 20-mer, bp722-741

5' ATG GGG CTG ATC TAC GTG AA 3'

katG-R amplification primer, 20-mer, bp1250-1231

5' GGT GTT CCA GCC AGC GAC GC 3'

katG-5s sequencing primer, 20-mer, bp722-741

5' ATG GGG CTG ATC TAC GTG AA 3'

katG-3s sequencing primer, 20-mer, bp1250-1231

5' GGT GTT CCA GCC AGC GAC GC 3'

SEQ ID NO. 6

SEQ ID NO. 7

SEO ID NO. 8

SEO ID NO. 9

SEO ID NO. 10

661 gctcgggat gaggttaca gcggtaagcg ggatctggag aaccgctgg ccgcggtgaa
721 gatggggctg atctacgtga acccggaggg gccgaacgg aaccggacg catggccatg
781 gctgatcgac ggcggtcaca ctttcggtga catggccatg aacgacgtcg aacacagggc
841 gctgatcgtc ggcggtcaca ctttcggtaa gaccatggc gccggccgg ccgatctggt
901 cggccccgaa cccgaggctg ctcgcgtgag gcagatggc ttgggctgga aggctcgta
961 tggcaccgga accggtaagg acgcgatcac cagcggcatg gaggtcgtat ggagcacac
1021 cccgacgaaa tgggacaaca gtttcctcga gatcctgtac ggctacgatg gggagctgaa

1081 gaagageet getggegett ggeaatacae egecaaggae ggegeeggtg eeggeaecat 1141 eeeggaeeeg tteggeggge eagggegete eeegaegatg etggeeaetg aceteteget 1201 gegggtggat eegatetatg ageggateae <u>greftegettgg etggaacaee</u> eegaggaatt 1261 ggeegaegag ttegeeaagg eetggtaeaa getgateeae egagaeatgg gteeegttge

oxyR-aphC intergenic region (PR)

PR-F amplification primer, 20-mer, bp451-470

5' ACC ACT GCT TTG CCG CCA CC 3'

PR-R amplification primer, 20-mer, bp687-668

5' CCG ATG AGA GCG GTG AGC TG 3'

PR-5s sequencing primer, 20-mer, bp451-470

5' ACC ACT GCT TTG CCG CCA CC 3'

SEQ ID NO. 13

PR-3s sequencing primer, 20-mer, bp687-668

5' CCG ATG AGA GCG GTG AGC TG 3'

SEQ ID NO. 14

SEQ ID NO. 15

361 atgccetggg ggtgcaccga gaccggette egaccaccge tegeogeaac gtegaetgge
421 teatategag aatgettgeg geaetgetga <u>accaetgett tgccgccacc</u> geggegaacg
481 egogaagece ggecaeggee ggetageace tettggegge gatgeegata aatatggtgt
541 gatatateae etttgeetga eagegaette aeggeaegat ggaatgtege aaccaaatge
601 attgteeget ttgatgatga ggagagteat gecaetgeta accaetggeg ateaatteee
661 egoetae<u>eag etcaecgete teategg</u>egg tgaeetgtee aaggeagge ceaaggage
721 eggegaetae tteaecaeta teaecagtga egaaaccca ggeaagtgge gggtggtgtt

mabA (isoniazid resistance)

mabA-F amplification primer, 20-mer, bp56-75

5' CCT CGC TGC CCA GAA AGG GA 3'
SEQ ID NO. 16
mabA-R amplification primer, 20-mer, bp303-284

5' ATC CCC CGG TTT CCT CCG GT 3'
SEQ ID NO. 17
mabA-5s sequencing primer, 20-mer, bp56-75

5' CCT CGC TGC CCA GAA AGG GA 3'
SEQ ID NO. 18

mabA-3s sequencing primer, 20-mer, bp303-284 5' ATC CCC CGG TTT CCT CCG GT 3'

SEO ID NO. 19

SEO ID NO. 20

- agegegacat acctgetgeg caattegtag ggegteaata caccegeage cagggetteg
- 61 ctgcccagaa agggatccgt catggtcgaa gtgtgctgag tcacaccgac aaacgtcacg
- 121 agcgtaaccc cagtgcgaaa gttcccgccg gaaatcgcag ccacgttacg ctcgtggaca
- 181 taccgattte ggeceggeeg eggegagaeg ataggttgte ggggtgaetg ccacagecae
- 241 tgaaggggcc aaacccccat tcgtatcccg ttcagtcctg gttaccggag gaaaccgggg
- 301 gatcgggctg gcgatcgcac agcggctggc tgccgacggc cacaaggtgg ccgtcaccca

rpsL/s12 (streptomycin resistance)

s12-F amplification primer, 20-mer, bp1-20

5' CGG TAG ATG CCA ACC ATC CA 3' SEQ ID NO. 21

s12-R amplification primer, 20-mer, bp384-365

5' GCA TCA GCC CTT CTC CTT CT 3' SEQ ID NO 22

s12-5s sequencing primer, 20-mer, bp1-20

5' CGG TAG ATG CCA ACC ATC CA 3' SEO ID NO. 23

s12-3s sequencing primer, 20-mer, bn384-365

5' GCA TCA GCC CTT CTC CTT CT 3' SEO ID NO. 24

SEO ID NO. 25

- cggtagatgc caaccatcca gcagctggtc cgcaagggtc gtcgggacaa gatcagtaag
- 61 gtcaagaccg cggctctgaa gggcagcccg cagcgtcgtg gtgtatgcac ccgcgtgtac 121 accaccacte egaagaagee gaacteggeg etteggaagg ttgeeegegt gaagttgaeg
- 181 agtcaggtcg aggtcacggc gtacattccc ggcgagggcc acaacctgca ggagcactcg
- 241 atggtgctgg tgcgcggcgg ccgggtgaag gacctgcctg gtgtgcgcta caagatcatc
- 301 cgcggttcgc tggatacgca gggtgtcaag aaccgcaaac aggcacgcag ccgttacggc
- 361 gctaagaagg agaagggctg atgccacgca aggggcccgc gcccaagcgt ccgttggtca

16S/rrs (streptomycin resistance)

16S-F amplification primer, 21-mer, bp5-25

5' GGT GAT CTG CCC TGC ACT TCG 3' 16S-R amplification primer, 21-mer, bp147-127

SEQ ID NO. 26

- 8 -

5' CGT CAC CCC ACC AAC AAG CTG 3'	SEQ ID NO. 27
16S-5s sequencing primer, 21-mer, bp5-25	
5' GGT GAT CTG CCC TGC ACT TCG 3'	SEQ ID NO. 28
16S-3s sequencing primer, 21-mer, bp147-127	
5' CGT CAC CCC ACC AAC AAG CTG 3'	SEQ ID NO. 29

SEQ ID NO. 30

- 1 cgtgggtgat ctgccctgca cttcgggata agcctgggaa actgggtcta ataccggata
- 61 ggaccacggg atgcatgtct tgtggtggaa agcgctttag cggtgtggga tgagcccgcg
- 121 gcctatcagc ttgttggtgg ggtgacg

embB-F amplification primer, 21-mer, bp7761-7781

embB (ethambutol resistance)

5' CGG CAA GCT GGC GCA CCT TCA 3'	SEQ ID NO. 31
embB-R amplification primer, 21-mer, bp8040-8020	
5' AGC CAG CAC ACT AGC CCG GCG 3	SEQ ID NO. 32
embB-5s sequencing primer, 21-mer, bp7761-7781	
5' CGG CAA GCT GGC GCA CCT TCA 3'	SEQ ID NO. 33
embB-3s sequencing primer, 21-mer, bp8040-8020	
5' AGC CAG CAC ACT AGC CCG GCG 3	SEO ID NO. 34

SEQ ID NO. 35

7741	cggcatgcgc	cggctgattc	nggcaagetg	gcgcaccttc	accctgaccg	acgccgtggt
7801	gatattcggc	ttcctgctct	ggcatgtcat	cggcgcgaat	tcgtcggacg	acggctacat
7861	cctgggcatg	gcccgagtcg	ccgaccacgc	cggctacatg	tccaactatt	tccgctggtt
7921	cggcagcccg	gaggatccct	tcggctggta	ttacaacctg	ctggcgctga	tgacccatgt
7981	cagcgacgcc	agtctgtgga	tgcgcctgcc	agacctggcc	gccgggctag	tatactaact

pncA (pyrazinamide resistance)

pncA-F amplification primer, 20-mer, bp1-20 5' ATG CGG GCG TTG ATC ATC GT 3'

SEQ ID NO. 36

pncA-F amplification primer, 20-mer, bp561-542

5' TCA GGA GCT GCA AAC CAA CT 3'
SEQ ID NO. 37
pncA-5s sequencing primer, 20-mer, bp1-20

5' ATG CGG GCG TTG ATC ATC GT 3'
SEQ ID NO. 38
pncA-3s sequencing primer, 20-mer, bp561-542

5' TCA GGA GCT GCA AAC CAA CT 3'
SEO ID NO. 39

SEQ ID. NO. 40

gyrA (fluoroquinilone/ciprofloxacin resistance)

gyrA-F amplification primer, 20-mer, bp2383-2402

5' CAG CTA CAT CGA CTA TGC GA 3'

gyrA-R amplification primer, 20-mer, bp2702-2683

5' GGG CTT CGG TGT ACC TCA TC 3'

gyrA-5s sequencing primer, 20-mer, bp2383-2402

5' CAG CTA CAT CGA CTA TGC GA 3'

gyrA-3s sequencing primer, 20-mer, bp2702-2683

5' GGG CTT CGG TGT ACC TCA TC 3'

SEQ ID NO. 43

SEO ID NO. 45

2341 cgaccggatc gaaccggttg acatcgagca ggagatgcag cgcagctaca tcgactatgc 2401 gatgagcgtg atcgtcggcc gcgcgctgcc ggaggtgcgc gacgggctca agcccgtgca 2461 tcgccgggtg ctctatgcaa tgttcgattc cggcttccgc ccggaccgca gccacgccaa

SEO ID NO. 49

2521 gteggecegg teggttgeeg agaceatggg caactaceae cegeaeggeg aegegtegat 2581 etacgaeage etggtgegea tggeceagee etggtegetg egetaeeege tggtggaegg 2641 eeagggeaae tteggetege eaggeaatga eecaeeggeg gegatgaggt aeaeegaage 2701 eeggetgaee eegttggega tggagatget gagggaaate gaegaggaga eagtegattt

23S (macrolide/azithromycin resistance)

5' GTA TTT CAA CAA CGA CTC CA 3'

23S-F amplification primer, 20-mer, bp2444-2463
5' CGA AAT TCC TTG TCG GGT AA 3'
SEQ ID NO. 46
23S-R amplification primer, 20-mer, bp2683-2664
5' GTA TTT CAA CAA CGA CTC CA 3'
SEQ ID NO. 47
23S-5s sequencing primer, 20-mer, bp2444-2463
5' CGA AAT TCC TTG TCG GGT AA 3'
SEQ ID NO. 48
23S-3s sequencing primer, 20-mer, bp2683-2664

SEQ ID NO. 50

2401 gccccagtaa acggcggtgg taactataac catcctaagg tag<u>cgaaatt ccttgrcggg</u>
2461 <u>taag</u>ttccga cctgcacgaa tggcgtaacg acttcccaac tgtctcaacc atagactcgg
2521 cgaaattgca ctacgagtaa agatgctcgt taggcggcg aggacgaaaa gaccccggga
2581 ccttcactac aacttggtat tggtgttcgg tacggtttgt gtaggatagg tgggagactt
2641 tgaagcacag acgccagttt gtgtggagtc gttgtrgaaa taccactctg atcgtattg

To facilitate detection of the sequencing products using real-time fluorescencebased electrophoresis apparatus (for example, a Visible Genetics OPENGENE™ sequencer), at least one of the sequencing primers is preferably labeled with a flourescent label. The label is selected for compatibility with the sequencing apparatus employed, and may be, for example, fluorescein or a cyanine dye such as CY5.0 OR CY5.5.

The primers of the invention are suitably packaged in a kit. This kit will contain individually packaged amplification and sequencing primers sets for each resistance gene to be evaluated by the kit. Thus, the kit of the invention includes at least 4 primers (two amplification and two sequencing primers), and preferably includes the primer sets for a plurality of resistance genes, most preferably the primer sets for all ten resistance genes.

The suitable protocol for the utilization of these primer sets in the evaluation of M. tuberculosis in clinical samples utilizes PCR amplification, followed by cycle sequencing. DNA for use in the test is obtained from a sample of sputum (100ul-10ml). The sputum sample is processed according to Standard Infectious Disease/Public Health Laboratory practices (Mycobacteriology Bench Manual, Laboratory Services Branch, December 1997, Ontario Ministry of Health). The sputum sample is homogenized, decontaminated and concentrated. Mycobacterial DNA is prepared directly from a portion of the concentrated cell sediment (100-200ul) using standard DNA extraction methods or commercially available kits.

Amplification of the DNA is performed using the amplification primer sets described above. PCR reagents can be prepared for individual reactions, or may be prepared as a master mix which can be used for multiple tests e.g., 10 PCR reactions. Exemplary combinations of reagents are summarized in the following table.

PCR mix		1 PCF	t	10 PCRs		final conc. / PCR
genomic DNA	(20ng/ul)		1.0 ul			20ng
(~0.5fM)						
10X PCR buffer I		2.5ul		25.0ul		1X
2.5mM dNTP mix	(1:1:1:1)	2.5ul		25.0ul		250uM
DMSO			1.3ul	13	.0ul	5%
Taq DNA polymerase	e (1U)	0.2ul		2.0ul		1 unit
molecular grade wate	r		16.5ul			165.0ul
MTB gene primers	(10uM)	1.0ul		10.0ul		10pmol per primer
total volume per PCR		25.0uI				

If the master mix as shown in the column labeled 10 PCRs is utilized, the mastermix contains all the necessary PCR reagents other than the genomic DNA. In this example, 24.0ul of the mastermix is added to a PCR tube, that already contains 1.0ul of genomic DNA, prior to the addition of the mineral oil overlay and placement in the thermocycler.

The genomic DNA preparation utilized must be of sufficient quality and integrity for robust and reproducible PCR. Suitable DNA preparation can be obtained using

- 12 -

the Gentra Puregene™ DNA isolation kit. The kit components are appropriate for the isolation of genomic DNA from blood, fresh or frozen tissue, archival material and paraffinembedded tissue.

Each primer pair is used to amplify a single gene region under the following conditions:

1.	Denaturation	94°C	5 minutes	1 cycle
2.	Denaturation	94°C	30 seconds	
	Annealing	60°C	30 seconds	35 cycles
	Extension	72°C	60 seconds	
3.	Extension	72°C	5 minutes	1 cycle
4.	Hold	6°C		

The temperature change during the cycles of the step 2 is desirably set to ramp at a rate of 1°C/sec.

After amplification, 2.0ul from the 25.0ul PCR is analysed for purity on a 0.8% agarose gel. Samples displaying single PCR product bands can be used directly for sequence analysis. The yield and purity of the PCR product determines the amount to be used in the subsequent cycle sequencing reaction. Comparable verification of sequencing purity is performed on each of the other amplification products.

Sequence analysis is carried out on the amplified product. The basic procedures and conditions are the same for each region. Accordingly, the invention will be exemplified using the rpoB gene.

For initial sequence analysis of rpoB, the rpoB-5s primer should be used. For confirmatory sequence analysis the rpoB-3s primer should be used. For each template to be sequenced, aliquot 3.0ul of each of the nucleotide termination mixes into four separate tubes marked <A>, <C>, <G> and <T> and store on ice until the sequencing mastermix is prepared.

Cycle sequencing mastermix

rpoB template	2.0ul
10X VGI Sequenace ™ buffer	2.5ul

- 13 -

DMSO	3.5ul
2.5uM dye-sequencing primer	2.0ul
PCR grade water	9.0ul
1:10 diluted Thermosequenase	0.5 ul
total volume	22.0ul

Mix the DMSO and other components in the mastermix well by repeated pipetting (5 times) with a micropipette. Store the mastermix on ice until ready to add to the nucleotide termination mixes.

Add 5.0ul of the mastermix to each of the four marked tubes containing the nucleotide termination mixes.

Add 8.0ul lightweight mineral oil to each of the four marked tubes containing the mastermix and nucleotide termination mixes.

Store on ice until ready to load into the thermocycler.

Parameters for cycle sequencing

1.	Denaturation	94°C	5 minutes	1X
2.	Denaturation	94°C	30 seconds	
	Annealing	60°C	30 seconds	35X
	Extension	72°C	60 seconds	
3.	Extension	72°C	5 minutes	1X
4.	Hold	6°C		

The temperature change during the cycles of the step 2 is desirably set to ramp at a rate of 1°C/sec,

At the end of the cycle sequencing reaction add 6.0ul of the Stop Loading Dye directly to each of the four tubes to stop the sequencing reaction. The sequencing samples are heated at 95°C for 2 minutes and then placed on ice before loading 2.0ul (from a total volume of 14ul) on the CLIPPERTM sequencer. The remainder of the sequencing reaction can be stored at -20°C for subsequent use.

The CLIPPERTM sequencer is set-up as described in the OPENGENE

Automated DNA Sequencing System User Manual. Run parameters for the CLIPPERTM sequencer are 54°C/ 1300volts/ 0.5sec sampling/35min run/50% laser power. The samples loaded included 2 ul each of the forward and reverse sequencing reaction products for the target gene, differentially labeled, for example with CY5.0 and CY5.5 cyanine dye labels.

Once the run is completed, the base-called data is analysed by comparison of the test sequence to the rpoB sequence database in GENELIBRARIANTM. This sequence alignment compares the test sequence to the standard control sequence and allows sequence ambiguities to be assessed. Once edited the test sequence can be screened for antibiotic resistance-associated mutations using GENELIBRARIANTM.

Testing for multiple types of antibiotic-resistance mutations can be carried out using a hierarchical assay, as summarized in Fig. 2. At present molecular biological methods for the detection of *M. tuberculosis* are only performed on AFB smear-positive sputum samples. These methods serve as confirmatory tests for the presence of *M. tuberculosis*. In addition to these molecular biological methods, the culture-based procedures for *M. tuberculosis* detection (BacTec liquid culture, agar plate and slant cultures) are performed in parallel. AFB smear-negative sputum samples are processed with only the culture-based detection procedures (Figure 1).

In the present invention both AFB smear-positive and smear-negative sputum samples can be processed using both culture-based and molecular biological methods. A limitation of the AFB stain methodology is it's limit of detection. If a sputum sample has a mycobacterial concentration of less than 5000 bacteria/ul the AFB stain will be negative. In addition to this is the observation that the decontamination procedure used to prepare the sputum sample usually kills 10-20% of the mycobacteria present. This would suggest that two-thirds of the AFB smear-negative samples potentially contain mycobacteria. In practice 10-20% of the AFB smear-negative samples are culture-positive for M. tuberculosis (Ontario Public Health Laboratory). This level of mycobacteria is easily detected by molecular biological methods and is therefore incorporated in the present invention.

The hierarchy proposed incorporates tests that specifically detect M. tuberculosis (rpoB), detect mutations in genes associated with resistance to the "first-line" antibiotics used to treat M. tuberculosis infections (rpoB, katG, rpsL/s12, PR, embB, pncA)

and detect other species of mycobacteria (23S) in the absence of *M. tuberculosis* (Figure 2). Group I analyses are performed before both Group II and Group III. Group I analysis will provide information on the antibiotic resistance status to rifampin (rpoB), isoniazid (katG), streptomycin (rpsL/s12) and azithromycin (23S). In addition the rpoB amplification indicates the presence of *M. tuberculosis* and in the absence of rpoB amplification the 23S sequence allows identification of most of the clinically relevant mycobacterial species. Group II analysis provides information on antibiotic resistance mutations in the "second-line" antibiotics used to treat *M. tuberculosis* infections namely, isoniazid (PR), ethambutol (embB), pyrazinamide (pncA) and ciprofloxacin (gyrA). Group III contains gene targets in which mutations associated with antibiotic resistance are infrequently found. This protocol permits specific gene targets to be examined according to the local treatment procedures since the both antibiotics used to treat *M. tuberculosis* infections, and thus the associated antibiotic resistance mutation patterns, vary geographically. As shown in

Figure 2 the culture-based methods are performed in parallel. The molecular biological methods would permit the identification of *M. tuberculosis* from both AFB smear-positive and smear-negative sputum samples and further provide information on the antibiotic resistance profile of these samples well in advance of current culture-based methods. This information would be crucial to the initiation of appropriate and effective antibiotic treatment regimens for *M. tuberculosis* infections.

Examples

A pool of DNA samples from antibiotic-sensitive *M. tuberculosis* isolates was obtained from the LCDC, Health and Welfare Canada. Ottawa, Ontario. Wild-type sequence traces, for all gene targets known to harbor mutations in antibiotic-resistant *M. tuberculosis*, were generated.

A panel of DNA samples from five phenotypic streptomycin-resistant *M. tuberculosis* isolates was obtained from the Public Health Laboratory, Ontario Ministry of Health, Toronto, Ontario. These DNA samples were examined for antibiotic resistance-associated mutations in all 10 antibiotic gene targets listed above. Streptomycin resistance-associated mutations were detected in the rpsL/sl2 gene in four isolates. Parallel antibiotic resistance-associated mutations in the rpoB (rifampin), katG (isoniazid), PR (isoniazid).

embB (ethambutol), pncA (pyrazinamide) and gyrA (ciprofloxacin) genes were also identified which underscores the importance of examining all the gene targets for first-line antibiotics used in the treatment of *M. tuberculosis*. A summary of the results is shown in Table 1.

The following references are cited herein and are incorporated herein by reference for all states which allow such incorporation.

- DL Williams et al. (1994). Characterisation of rifampin resistance in pathogenic mycobacteria. Antimicrob Agents Chemother 38: 2380-2386.
- WH Haas et al. (1997). Molecular analysis of katG gene mutations in strains of Mycobacterium tuberculosis complex from Africa. Antimicrob Agents Chemother 41: 1601-1603.
- S Sreevatsan et al. (1997). Analysis of the oxyR-ahpC region in isoniazidresistant and –susceptible Mycobacterium tuberculosis complex organisms recovered from diseased humans and animals in diverse localities. Antimicrob Agents Chemother 41: 600-606.
- A Telenti et al. (1994). Genotypic assessment of isoniazid and rifampin resistance in Mycobacterium tuberculosis: a blind study at the reference laboratory level. Antimicrob Agents Chemother 35: 719-723.
- ^e C Katsukawa et al. (1997). Characterisation of the rpsL and rrs genes of streptomycin-resistant clinical isolates of Mycobacterium tuberculosis in Japan. J Appl Microbiol 83: 634-640.
- C Katsukawa et al. (1997). Characterisation of the rpsL and rrs genes of streptomycin-resistant clinical isolates of Mycobacterium tuberculosis in Japan. J Appl Microbiol 83: 634-640.
- MA Lety et al. (1997). A single point mutation in the embB gene is responsible for resistance to ethambutol in Mycobacterium smegmatis. Antimicrob Agents Chemother 41: 2629-2633.
- A Scorpio et al. (1997). Characaterisation of pncA mutations in pyrazinamideresistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 41: 540-543.

- C Xu et al. (1996). Fluoroquinilone resistance associated with specific gyrase mutations in clinical isolates of multidrug-resistant Mycobacterium tuberculosis. J Infect Disease 174: 1127-1130.
- KA Nash et al. (1995). Genetic basis of macrolide resistance in Mycobacterium avium isolated from patients with disseminated disease. Antimicrob Agents Chemother 39: 2625-2630.

ž

*

ž

¥

¥

23s (azithromycin)

(3)
(D)
46
60
(f)
1.5
13
U1
2
Ø
fu .
TUT
11 . 1
15
10
1a
-

gene (antiblotic) rpoB (iflampin) katG.1 (teoniaz(d) oxyR-ahpC PR (isoniaz(d) fabG (soniaz(d) fabG (soniaz(d)) 16s/rts (streptomycin)	OPH#1 bp/codon/aa cac626lac, His526Tyr agc513acc, Sef513Thr wt wt	OPH#2 bp/codon/aa tcg553ttg, Ser553Leu agc513acc, Se613Thr w1 w1 w1 w1	OPH#3 bp/codon/aa cac526gac, His526Asp wt wt wt wt wt wt wt wt wt	OPH#4 up/codon/aa wt wt wt wt wt wt wt wt wt	OPH#11 bp/codon/aa wt wt g541a wt wt wt wt wt
embB (ethambutol)	w	gtc292ttc, val292phe	w	wt	wt
pncA (pyrazinamide)	tcc65tct, Ser65Ser	w	att133aat, lle133Asn	wt	toc65lct, Ser65Ser
gyrA (ciprofloxacin)	agc95acc, Ser95Thr	agc95acc, Ser95Thr	agc95acc, Ser95Thr	agc95acc, Ser95Thr	agc95acc, Ser95Thr


CLAIMS

- I. A method for detection and characterization of Mycobacterium tuberculosis present in a sample, comprising the steps of:
 - (a) obtaining a sputum sample suspected of containing M. tuberculosis,
- (b) performing a first sequencing procedure, with or without prior amplification, on the sample, said sequencing procedure generating sequencing fragments for evaluation of the rpoB, katG, rpsL/s12 and 23S genes for the presence of antibiotic-resistance inducing mutations when M. suberculosis is present in the sample, wherein primers for the sequencing of the rpoB gene are selected such that the generation of sequencing products for this gene is indicative of the presence of M. tuberculoris in the sample; and
- (c) if M. tuberculasis is detected as a result of generation of sequencing products for the 170R gene in step (b), performing a second sequencing procedure, with or without prior amplification, on the sample to evaluate at least one additional M. tuberculasis gene for the presence of amibiotic-resistance inducing mutations.
- The method of claim 1, wherein the second sequencing procedure evaluates PR, embB pncA and gyrA genes for the presence of antibiotic-resistance mutations.
- 3. The method of claim 1, fluther comprising the step of performing a third sequencing procedure when M. tuberculosis was detected in step (b), separate from the first and second sequencing procedures, to evaluate 168/ns and mahA genes for the presence of antibiotic-resistance mutations.
- 4. The method of any of claims 1 to 3, wherein the first sequencing procedure for mob is performed using amplification primers as set forth in Seq. ID Nos. 1 and 2 and sequencing primers as set forth in Seq. ID. Nos. 3 and 4.
- 5. The method of any of claims 1 to 4, wherein the first sequencing procedure for katG is performed using amplification primers as set forth in Seq. ID Nos. 6 and 7 and sequencing primers as set forth in Seq. ID. Nos. 8 and 9.


- 6. The method of any of claims 1 to 5, wherein the first sequencing procedure for rpsL/s12 is performed using amplification primers as set forfit in Seq. ID Nos. 21 and 22 and sequencing primers as set forth in Seq. ID. Nos. 23 and 24.
- The method of any of claims 1 to 6, wherein the second sequencing procedure for 23S is performed using amplification primers as set forth in Seq. ID Nos. 46 and 47 and sequencing primers as set forth in Seq. ID. Nos. 48 and 49.
- 8. The method of any of claims 1 to 7, wherein the second sequencing procedure for PR is performed using amplification primers as set forth in Seq. ID Nos. 11 and 12 and sequencing primers as set forth in Seq. ID. Nos. 13 and 14.
- The method of any of claims 1 to 8, wherein the second sequencing procedure for pncA is performed using amplification primers as set forth in Seq. ID Nos. 36 and 37 and sequencing primers as set forth in Seq. ID. Nos. 38 and 39.
- 10. The method of any of claims 1 to 9, wherein the second sequencing procedure for cmbB is performed using amplification primers as set forth in Seq. ID Nos. 31 and 32 and sequencing primers as set forth in Seq. ID. Nos. 33 and 34.
- 11. The method of any of claims 1 to 10, wherein the second sequencing procedure for gyrA is performed using amplification princes as set forth in Seq. 1D Nos. 41 and 42 and sequencing primers as set forth in Seq. 1D. Nos. 43 and 44.
- 12. The method of any of claims 2 to 11, wherein the third sequencing procedure for 16S/ms is performed using amplification primers as set forth in Seq. ID Nos. 26 and 27 and sequencing primers as set forth in Seq. ID. Nos. 28 and 29.

- 13. The method of any of claims 2 to 12, wherein the third sequencing procedure for mahA is performed using amplification primers as set forth in Seq. ID Nos. 16 and 17 and sequencing primers as set forth in Seq. ID. Nos. 18 and 19.
- 14. A kit for evaluation of smilliotic-resistance mutations in a sample of Mycobacterium tuberculosis, comprising pairs of amplification primers and matched pairs of sequencing primers for amplification and sequencing the at least the rpoB, ketG, rpsL/s12 and 23S genes of M. tuberculoris, characterized in that the amplification and sequencing primer pairs include at least one combination of primer pairs selected from among:
- amplification primers of Seq. ID Nos. 1 and 2 in combination and sequencing primers of Seq. ID Nos. 3 and 4;
- (b) amplification primers of Seq. ID Nos. 6 and 7 in combination and sequencing primers of Seq. ID Nos. 8 and 9;
- (c) amplification primers of Seq. ID Nos. 11 and 12 in combination and sequencing primers of Seq. ID Nos. 13 and 14;
- (d) amplification primers of Seq. ID Nos. 16 and 17 in combination and sequencing primers of Seq. ID Nos. 18 and 19;
- (e) amplification primers of Seq. ID Nos. 21 and 22 in combination and sequencing primers of Seq. ID Nos. 23 and 24;
- (f) _ amplification primers of Seq. 1D Nos. 26 and 27 in combination and sequencing primers of Seq. 1D Nos. 28 and 29;
- amplification primers of Seq. ID Nos. 31 and 32 in combination and sequencing primers of Seq. ID Nos. 33 and 34;
- amplification primers of Seq. ID Nos. 36 and 37 in combination and sequencing primers of Seq. ID Nos. 38 and 39;
- (i) amplification primers of Seq. ID Nos. 41 and 42 in combination and sequencing primers of Seq. ID Nos. 43 and 44; and
- amplification primers of Seq. ID Nos. 46 and 47 in combination and sequencing primers of Seq. ID Nos. 48 and 49.

1/2



2/2



Ü

4

en en

14

ļ.á

Ø 004

5eb-23-01 02:56P NoAb Diagnostics 02/23/2001 12:29 9704680104

905 814 5241 OPPEDAHL&LARSON LLP P.04 PAGE 03/04

COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My citizenship, residence and post office address are as listed below next to my name.

I believe I am the original, first and [x] sole() joint inventor of the subject matter which is claimed and for which a patent is supply on the invention entitled; <u>Residence and Kit for Characterization of Antibiotic-Resistance Mutoritons in Nivrobacterium Tuberculosis</u>

ne spe	SCROMON OF Which
a) []	Is attached hereto.
b) []	was filed on as Application Serial No and was amended on
(c) (x]	was described and claimed in International Application No. PCT/CA99/01177 filed on December 10, 1999 and amended on

Acknowledgment of Duty of Disclosure

I hereby state that I have reviewed and understood the content of the above identified specification, including the colume, as amended by any amendment reviewed to above, I acknowledge the duty to disclose information which is material to the patentability of the subject matter claimed in this application in accordance with Title 37, Code of Federal Regulations 9 1,56(a).

35 U.S.C. § 120

I hereby claim the benefit under Title 36, United States Code, § 120 of any United States application(s) or 393 (of any PCT international application designating the United States of America, tised below and, inside a subject matter of each of the claims of this application is not discioused in the prior United States or PCT International application in the menner provided by the first paragraph of 36 U.S.C. § 112, 1 acknowledge the duty to disclose material information as defined in 37 CFR § 1:56 which becames variable between the filling date of the prior application and the national or PCT international filling date of this application:

(Application Serial No.)	(Filing Date)	(Sumus)(patented,pending,ubandoned)	(Patent No. if applicable)
(Application Sense No.)	(Filing Date)	(Status)(putertact pending abendoned)	(Patent No. If applicable)

Power of Attorney

I hereby appoint Carl Oppedahl, PTO Reg. NO. 32,746 and Marina T. Larson, PTO Reg. No. 32,038, and D'Atoy Straub, PTO Reg. No. 47,118, of the firm of OTPEDAHL & LARSON LLP, having office at P.O. Box 6068, Dillon, Colorado 80435-5068, as attomays to prosecute this application and to transact all business in the Petent and Trademark Office connected therewith.



PRINT THEODER GYES

DIRECT TELEPHONE CALLS TO: OPPEDANL & LARSON LLP

(970)468-6600

02/23/2001 12:29

Feb-23-01 02:57P NoAb Diagnostics

905 814 5241 OPPEDANLALARSON LLP

Ø1005 P.05 P.05 PAGE 04/04

Claim for Priority

9704680104

I hereby daim foreign priority benefits under 35 U.S.C. § 119 (a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any FCT intermetation application which designated at least one on inity other than the United States of America, listed below any lac identified below any foreign applications for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which

Notify to Calmined.						
EARLIEST FOREIGN APPLICATION(S), FILED WITHIN TWELVE MONTHS (6 MONTHS FOR DESIGN) PRIOR TO SAID APPLICATION						
COUNTRY	APPLICATION NO.	DATE OF FILING (day/month/year)	DATE OF ISSUE (day/month/year)	PRIORITY	CERTIFIED COPY ATTACHED	
				YES[]NO[]	YES[] NOL]	
PORTION APPLICATION (D. S'ANY, PESTO MORE THAN 12 MONTHS (6 MICHTHS FOR DESIGN) DRIOR TO SALT APPLICATION						
COUNTRY	APPLICATION NO.	DATE OF FILING (day/maph/year)	DATE OF ISSUE (day/month/year)			

Provisional Application

I hereby claim the benefit under 35 U.S.C § 118(e) of any United States provisional application(s) listed below.

60/111.794 December 11, 1996 (filing date) (application number)

I hereby deciare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by one or impresonment or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

NAME OF SILE OR FIRST INVENTOR SHIPMAN		w	FIRST NAME ROBERT	MEDDLE NAME
RESIDENCE S CITY OF REI Mississau		NCE	STATE OR COLINTRY OF REASSENCE	COUNTRY OF CITIZENSHIP Canada
roet office Abbrese 130 Vista Boulevard		env Mississeuga, Ontario	STATEMOOUNTRY ZIP CODE Canada L5M 1V9	
FEB. 23, 2001		SICHATURE LUDMCEN		

Signature for additional joint inventor ettached. Numer of Pages
 Signature by Administrator(trin) or legal representative for deceased or incapacitated inventor. Number of Pages
 Segnature for inventor who refuses to sign or cannot be reached by person authorized under 97 CPR § 14.7. Number of Pages